electroCore Inc. (ECOR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, electroCore Inc. (NASDAQ: ECOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $8.11 (-3.68% 1D, market cap $73.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ECOR ranks #721 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -28.0%, cap $78.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $78.9M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ECOR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.49) and Max Pain ($8.52) forces dealer call-delta covering toward $13.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
electroCore Inc. (ECOR) dropped -3.68% to $8.11, trading at 45% of its 52-week range ($4.41 – $12.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third
Joshua Lev, co-CEO, president and CFO of electroCore (NASDAQ:ECOR), said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand product indications and re
Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment grou
electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug
Controlled study in 50 healthy adults suggests accelerated learning, improved executive efficiency and stronger behavioral coordination.ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR)
ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Toronto 20
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +27.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ECOR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ECOR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, electroCore Inc. (ECOR) ranks #721 by composite RQD confidence (38/100, grade D-) and #701 by equity capitalization ($73.1M). Within this direct 5-issuer industry benchmark cohort, ECOR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ECOR at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ECOR
ACTIVE
electroCore Inc. | D- | 38/100 | — | 86.8% | -35.0% | -3.68% | $73.1M | Benchmark Subject |
| OM Outset Medical Inc. | D- | 35/100 | — | 39.1% | -28.0% | -3.46% | $78.8M | /om-vs-ecor → |
| HYPR Hyperfine Inc. (Class A) | D | 45/100 | — | 49.8% | -35.0% | -5.23% | $78.9M | /hypr-vs-ecor → |
| STXS Stereotaxis Inc. | E | 30/100 | — | 52.7% | -35.0% | -6.21% | $91.2M | /stxs-vs-ecor → |
| NRXS Neuraxis Inc. | E | 32/100 | — | 84.2% | -35.0% | -0.26% | $94.8M | /nrxs-vs-ecor → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), electroCore Inc. (ECOR) reported GAAP revenue of $32.0M (+27.2% vs. FY2024 revenue of $25.2M , and +99.8% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$8.2M, and free cash flow of -$8.3M (-18.8% YoY). On the balance sheet, ECOR closed FY2025 with $18.7M in total assets against $6.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $32.0M | -$14.0M | -$8.2M | -$8.3M | $18.7M | $6.6M |
| FY2024 (FY) | 2024-12-31 | $25.2M | -$11.9M | -$6.9M | -$6.9M | $20.5M | — |
| FY2023 (FY) | 2023-12-31 | $16.0M | -$18.8M | -$14.7M | -$14.7M | — | — |
As of 2026-11-01, electroCore Inc. (NASDAQ: ECOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $8.11 (-3.68% 1D, market cap $73.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ECOR ranks #721 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ECOR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 86.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -28.0%, cap $78.8M) and HYPR (Hyperfine Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $78.9M). Among the 5-stock peer group, ECOR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
Per ECOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560258), electroCore Inc. generated $32.0M in revenue (+27.2% YoY), -$14.0M in net income, and -$8.3M in free cash flow against $18.7M in total assets and $6.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ECOR last traded at $8.11 (-3.68% on volume of 33,035 shares), positioning the stock -14.54% below its 50-day simple moving average ($9.49) and +4.78% above its 200-day simple moving average ($7.74). Across its 52-week range of $4.41 to $12.70, ECOR sits at the 44.6% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.10 to $9.12).
Why ECOR Stock dropped -3.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.